

# Marion S Subklewe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1990611/publications.pdf>

Version: 2024-02-01

151  
papers

10,043  
citations

53794

45  
h-index

46799

89  
g-index

161  
all docs

161  
docs citations

161  
times ranked

13721  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytokine release syndrome. , 2018, 6, 56.		1,055
2	Efficient Presentation of Phagocytosed Cellular Fragments on the Major Histocompatibility Complex Class II Products of Dendritic Cells. Journal of Experimental Medicine, 1998, 188, 2163-2173.	8.5	583
3	Structures of the human and Drosophila 80S ribosome. Nature, 2013, 497, 80-85.	27.8	474
4	Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood, 2016, 128, 686-698.	1.4	456
5	The DNA Inflammasome in Human Myeloid Cells Is Initiated by a STING-Cell Death Program Upstream of NLRP3. Cell, 2017, 171, 1110-1124.e18.	28.9	431
6	Advances in cancer immunotherapy 2019 – latest trends. Journal of Experimental and Clinical Cancer Research, 2019, 38, 268.	8.6	401
7	Human Cd4+ T Lymphocytes Consistently Respond to the Latent Epstein-Barr Virus Nuclear Antigen Ebna1. Journal of Experimental Medicine, 2000, 191, 1649-1660.	8.5	323
8	2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2021, 138, 2753-2767.	1.4	305
9	Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. Journal of Immunology, 1999, 163, 6762-8.	0.8	287
10	A Monocyte Conditioned Medium Is More Effective Than Defined Cytokines in Mediating the Terminal Maturation of Human Dendritic Cells. Blood, 1997, 90, 3640-3646.	1.4	222
11	Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia, 2019, 33, 64-74.	7.2	212
12	Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia, 2016, 30, 484-491.	7.2	201
13	CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330. Blood, 2014, 123, 356-365.	1.4	168
14	Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. Journal of Clinical Oncology, 2017, 35, 536-543.	1.6	168
15	CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood, 2021, 138, 2499-2513.	1.4	160
16	Features of Human CD3+CD20+ T Cells. Journal of Immunology, 2016, 197, 1111-1117.	0.8	144
17	Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells. Frontiers in Immunology, 2018, 9, 385.	4.8	144
18	Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia, 2020, 34, 3161-3172.	7.2	141

#	ARTICLE	IF	CITATIONS
19	Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab. <i>Journal of Hematology and Oncology</i> , 2015, 8, 111.	17.0	131
20	T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. <i>Journal of Hematology and Oncology</i> , 2015, 8, 93.	17.0	127
21	T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. <i>Leukemia</i> , 2021, 35, 1843-1863.	7.2	123
22	Recent developments in immunotherapy of acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 142.	17.0	118
23	The BiTE (bispecific Tâ€cell engager) platform: Development and future potential of a targeted immunoâ€oncology therapy across tumor types. <i>Cancer</i> , 2020, 126, 3192-3201.	4.1	116
24	Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy. <i>Transfusion Medicine and Hemotherapy</i> , 2019, 46, 15-24.	1.6	107
25	Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 1598-1608.	7.2	106
26	Dendritic Cells Cross-Present Latency Gene Products from Epstein-Barr Virusâ€Transformed B Cells and Expand Tumor-Reactive Cd8+ Killer T Cells. <i>Journal of Experimental Medicine</i> , 2001, 193, 405-412.	8.5	104
27	Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. <i>Haematologica</i> , 2018, 103, 1853-1861.	3.5	96
28	Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. <i>Transplant Immunology</i> , 2007, 17, 203-210.	1.2	84
29	A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, 456-465.	3.5	84
30	T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. <i>Nature Biomedical Engineering</i> , 2021, 5, 1246-1260.	22.5	80
31	An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging. <i>PLoS ONE</i> , 2015, 10, e0120925.	2.5	78
32	Bifunctional PD-1 Ã— Î±CD3 Ã— Î±CD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia. <i>Blood</i> , 2018, 132, 2484-2494.	1.4	73
33	Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse. <i>Haematologica</i> , 2014, 99, 1317-1325.	3.5	71
34	Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML).. <i>Journal of Clinical Oncology</i> , 2020, 38, 7508-7508.	1.6	70
35	Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus. <i>Blood</i> , 1999, 94, 1372-1381.	1.4	63
36	Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. <i>Leukemia</i> , 2015, 29, 828-838.	7.2	63

#	ARTICLE	IF	CITATIONS
37	Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. <i>Leukemia</i> , 2021, 35, 62-74.	7.2	63
38	Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 313-322.	7.2	61
39	Activating FLT3 Mutants Show Distinct Gain-of-Function Phenotypes In Vitro and a Characteristic Signaling Pathway Profile Associated with Prognosis in Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2014, 9, e89560.	2.5	60
40	Determinants of response and resistance to CAR T cell therapy. <i>Seminars in Cancer Biology</i> , 2020, 65, 80-90.	9.6	59
41	BiTEs better than CAR T cells. <i>Blood Advances</i> , 2021, 5, 607-612.	5.2	59
42	Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse. <i>Leukemia</i> , 2015, 29, 377-386.	7.2	58
43	Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. <i>Science Advances</i> , 2021, 7, .	10.3	56
44	Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE <sup>®</sup> (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 833-833.	1.4	55
45	CD86 and IL-12p70 Are Key Players for T Helper 1 Polarization and Natural Killer Cell Activation by Toll-Like Receptor-Induced Dendritic Cells. <i>PLoS ONE</i> , 2012, 7, e44266.	2.5	54
46	Impaired function and delayed regeneration of dendritic cells in COVID-19. <i>PLoS Pathogens</i> , 2021, 17, e1009742.	4.7	52
47	GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. <i>Blood</i> , 2022, , .	1.4	51
48	Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia. <i>Haematologica</i> , 2016, 101, 932-940.	3.5	50
49	The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. , 2022, 10, e004475.		50
50	Diagnosis of <sc>CLL</sc> revisited: increased specificity by a modified fiveâ€marker scoring system including <sc>CD</sc>200. <i>British Journal of Haematology</i> , 2017, 179, 480-487.	2.5	49
51	Association of Human Leukocyte Antigen Haplotypes with Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation. <i>Transplantation</i> , 2006, 82, 1093-1100.	1.0	48
52	Epsteinâ€Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. <i>Annals of Hematology</i> , 2006, 85, 478-484.	1.8	48
53	Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2019, 8, 579.	2.4	48
54	Dendritic Cell Maturation Stage Determines Susceptibility to the Proteasome Inhibitor Bortezomib. <i>Human Immunology</i> , 2007, 68, 147-155.	2.4	46

#	ARTICLE	IF	CITATIONS
55	A Web- and App-Based Connected Care Solution for COVID-19 In- and Outpatient Care: Qualitative Study and Application Development. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e19033.	2.6	46
56	Expression of Surface Markers on Alveolar Macrophages From Symptomatic Patients with HIV Infection as Detected by Flow Cytometry. <i>Chest</i> , 1994, 105, 1324-1334.	0.8	45
57	CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. <i>Blood</i> , 2021, 137, 1037-1049.	1.4	45
58	Immunotherapy for Acute Myeloid Leukemia. <i>Seminars in Hematology</i> , 2015, 52, 207-214.	3.4	44
59	Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. <i>Blood</i> , 2021, 138, 2655-2669.	1.4	43
60	Presentation of Epstein-Barr virus latency antigens to CD8+, interferon- $\gamma$ -secreting, T lymphocytes. <i>European Journal of Immunology</i> , 1999, 29, 3995-4001.	2.9	42
61	Clinical overview of anti-CD19 BiTE <sup>®</sup> and ex vivo data from anti-CD33 BiTE <sup>®</sup> as examples for retargeting T cells in hematologic malignancies. <i>Molecular Immunology</i> , 2015, 67, 58-66.	2.2	40
62	Hepatosplenic T-cell lymphoma in a patient with Crohn's disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 433-436.	17.8	39
63	New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1093-1103.	4.2	38
64	Discovery of Highly Potent p53-MDM2 Antagonists and Structural Basis for Anti-Acute Myeloid Leukemia Activities. <i>ACS Chemical Biology</i> , 2014, 9, 802-811.	3.4	38
65	PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. <i>European Radiology Experimental</i> , 2020, 4, 63.	3.4	38
66	Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission. <i>Journal of Translational Medicine</i> , 2011, 9, 151.	4.4	36
67	COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma. <i>HemaSphere</i> , 2021, 5, e603.	2.7	35
68	Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. <i>Blood Advances</i> , 2022, 6, 3606-3610.	5.2	35
69	Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party. <i>HemaSphere</i> , 2022, 6, e676.	2.7	35
70	Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML. <i>Leukemia Research</i> , 2014, 38, 964-969.	0.8	34
71	Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1875-1888.	4.1	34
72	A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1353-1362.	4.2	34

#	ARTICLE	IF	CITATIONS
73	Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy. <i>Journal of Clinical Oncology</i> , 2021, 39, 419-432.	1.6	34
74	RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade. <i>Leukemia</i> , 2020, 34, 1017-1026.	7.2	33
75	Severe <i>Candida glabrata</i> pancolitis and fatal <i>Aspergillus fumigatus</i> pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy – a case report. <i>BMC Infectious Diseases</i> , 2021, 21, 121.	2.9	33
76	Immunotherapy in Tumors. <i>Deutsches Ärzteblatt International</i> , 2015, 112, 809-15.	0.9	31
77	A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2010, 51, 447-455.	1.3	29
78	Targeting CD157 in AML using a novel, Fc-engineered antibody construct. <i>Oncotarget</i> , 2017, 8, 35707-35717.	1.8	27
79	Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients. <i>Annals of Hematology</i> , 2012, 91, 1051-1063.	1.8	26
80	End-of-Treatment Positron Emission Tomography After Uniform First-Line Therapy of B-Cell Posttransplant Lymphoproliferative Disorder Identifies Patients at Low Risk of Relapse in the Prospective German PTLD Registry. <i>Transplantation</i> , 2018, 102, 868-875.	1.0	26
81	A modular and controllable T cell therapy platform for acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2243-2257.	7.2	24
82	Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial. <i>Clinical and Translational Immunology</i> , 2020, 9, e1117.	3.8	23
83	Dendritic Cells Expand Epstein Barr Virus Specific CD8+ T Cell Responses More Efficiently Than EBV Transformed B Cells. <i>Human Immunology</i> , 2005, 66, 938-949.	2.4	21
84	Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells. <i>Oncology</i> , 2018, 7, e1472195.	4.6	21
85	Current strategies in immunotherapy for acute myeloid leukemia. <i>Immunotherapy</i> , 2013, 5, 63-78.	2.0	20
86	Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia – a phase 3 study. <i>Leukemia</i> , 2018, 32, 2558-2571.	7.2	20
87	Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL. <i>Blood</i> , 2022, 140, 2175-2179.	1.4	20
88	Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma. <i>International Journal of Hematology</i> , 2008, 88, 434-440.	1.6	19
89	Chimeric Antigen Receptor T Cells for Glioblastoma. <i>Neurology</i> , 2021, 97, 218-230.	1.1	19
90	Abundant glutamic acid decarboxylase (GAD)-reactive B cells in gad-antibody-associated neurological disorders. <i>Annals of Neurology</i> , 2019, 85, 448-454.	5.3	18

#	ARTICLE	IF	CITATIONS
91	Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus. <i>Blood</i> , 1999, 94, 1372-1381.	1.4	18
92	SIRP $\beta$ -antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells. <i>Oncotarget</i> , 2017, 8, 11284-11301.	1.8	17
93	Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies. <i>Haematologica</i> , 2022, 107, 2096-2107.	3.5	17
94	Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients. <i>Oncolmmunology</i> , 2016, 5, e1178421.	4.6	15
95	CAR T-Cells for CNS Lymphoma: Driving into New Terrain?. <i>Cancers</i> , 2021, 13, 2503.	3.7	15
96	Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus. <i>Blood</i> , 1999, 94, 1372-81.	1.4	15
97	Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection. <i>HemaSphere</i> , 2021, 5, e530.	2.7	14
98	Combination Chemoimmunotherapy Using Alemtuzumab, Fludarabine, Cyclophosphamide, and Doxorubicin (Campath-FCD) Is an Effective First-Line Regimen in Peripheral T-Cell Lymphomas.. <i>Blood</i> , 2004, 104, 2640-2640.	1.4	14
99	Extramedullary manifestation of a donor-derived acute myeloid leukemia in a liver transplant patient. <i>Leukemia</i> , 2004, 18, 2050-2053.	7.2	13
100	Generation of EBV-specific T Cells for Adoptive Immunotherapy: A Novel Protocol Using Formalin-fixed Stimulator Cells to Increase Biosafety. <i>Journal of Immunotherapy</i> , 2007, 30, 817-824.	2.4	13
101	SIRP $\beta$ - $\beta$ CD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells. <i>Journal of Hematology and Oncology</i> , 2021, 14, 155.	17.0	13
102	Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment. <i>Blood Advances</i> , 2022, 6, 3022-3026.	5.2	13
103	Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials. <i>Transplantation</i> , 2018, 102, 1914-1923.	1.0	11
104	Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells. <i>Blood</i> , 2020, 136, 33-34.	1.4	11
105	Induction of Antigen-Specific T-Cell Responses through Dendritic Cell Vaccination in AML: Results of a Phase I/II Trial and Ex Vivo Enhancement By Checkpoint Blockade. <i>Blood</i> , 2016, 128, 764-764.	1.4	10
106	Leukemic stem cells as a target for eliminating acute myeloid leukemia: Gaps in translational research. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 175, 103710.	4.4	9
107	Impairment of Circulating Myeloid Dendritic Cells in Immunosuppressed Renal/Pancreas Transplant Recipients. <i>Transplantation</i> , 2006, 82, 779-787.	1.0	8
108	Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis. <i>Blood Advances</i> , 2019, 3, 2696-2699.	5.2	8

#	ARTICLE	IF	CITATIONS
109	Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells. <i>HemaSphere</i> , 2021, 5, e533.	2.7	8
110	The PI3K $\alpha$ -Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression. <i>Frontiers in Immunology</i> , 2021, 12, 608625.	4.8	8
111	Integrated multiomic approach for identification of novel immunotherapeutic targets in AML. <i>Biomarker Research</i> , 2022, 10, .	6.8	8
112	Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting $\alpha$ CD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 602802.	4.8	7
113	Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1705-1718.	4.2	6
114	Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA). <i>Blood</i> , 2020, 136, 39-40.	1.4	6
115	Ten things the hematologist wants you to know about CAR-T cells. <i>Intensive Care Medicine</i> , 2020, 46, 1243-1245.	8.2	5
116	A Phase II Immunochemotherapy Study with Alemtuzumab, Fludarabine, Cyclophosphamide, and Doxorubicin (Campath-FCD) in Peripheral T-Cell Lymphomas.. <i>Blood</i> , 2006, 108, 2721-2721.	1.4	5
117	Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients. <i>Blood</i> , 2015, 126, 816-816.	1.4	5
118	Radiologic and Pathologic Features of a Posttransplantation Primary Central Nervous System Lymphoma Demonstrating Epstein-Barr Virus $\alpha$ Positive Hodgkin Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 535-537.	1.4	4
119	Chimeric Antigen Receptor $\alpha$ Modified T Cells and T Cell $\alpha$ Engaging Bispecific Antibodies: Different Tools for the Same Job. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 218-233.	2.3	4
120	High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008). <i>Blood</i> , 2013, 122, 619-619.	1.4	4
121	RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AML. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1505-1515.	4.2	3
122	Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction. <i>Haematologica</i> , 2019, 104, e510-e513.	3.5	3
123	Sarcoid-Like Reaction in Non-Hodgkin $\alpha$ TMs Lymphoma $\alpha$ A Diagnostic Challenge for Deauville Scoring on 18F-FDG PET/CT Imaging. <i>Diagnostics</i> , 2021, 11, 1009.	2.6	3
124	Dendritic Cells for the Induction of EBV Immunity. <i>Recent Results in Cancer Research</i> , 2002, 159, 38-43.	1.8	3
125	Predictors of Efficacy for Blinatumomab in BCP-ALL Patients: Non-Responders Show Impaired CD19-BITE $\alpha$ -Mediated Cytotoxicity in Vitro. <i>Blood</i> , 2019, 134, 2632-2632.	1.4	3
126	Single-Center Experience with Axicabtagene-Ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Comparable Response Rates and Manageable Toxicity. <i>Blood</i> , 2020, 136, 34-35.	1.4	3



#	ARTICLE	IF	CITATIONS
127	Proposal For a Novel Scoring System For The Diagnosis Of CLL. Blood, 2013, 122, 4150-4150.	1.4	3
128	CHOP but Not Bendamustine Reverses EZH2 Y641 Mutation Induced MHC-I/II Loss in Human Lymphoma Models. Blood, 2021, 138, 2391-2391.	1.4	3
129	High Bacterial Abundances of Dorea and Pediococcus in the Gut Microbiome Linked to Expansion, Immune Checkpoint Expression and Efficacy of CD19-Directed CAR T-Cells in Patients with r/r DLBCL. Blood, 2021, 138, 2792-2792.	1.4	3
130	Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology. American Journal of Clinical Oncology: Cancer Clinical Trials, 0, Publish Ahead of Print, .	1.3	3
131	Advanced systemic mastocytosis as a mimicker of metastatic clear cell renal cell carcinoma. Leukemia Research, 2012, 36, 799-801.	0.8	2
132	Bendamustine and the immune system: a wolf in sheep's clothing?. Leukemia and Lymphoma, 2015, 56, 837-838.	1.3	2
133	Transformation of diffuse large B cell lymphoma into dendritic sarcoma under CAR T cell therapy detected on 18F-FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1692-1693.	6.4	2
134	Characterization of clinical pharmacokinetics and exposure-response relationships of AMG 330, a bispecific CD33 T-cell engager antibody construct, in patients with relapsed/refractory AML.. Journal of Clinical Oncology, 2020, 38, 7536-7536.	1.6	2
135	Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis. Blood, 2021, 138, 3822-3822.	1.4	2
136	Evolving Exhaustion of T Cells during the Course of the Disease in AML Can be Abrogated By CD33 BiTE Å® Construct Mediated Cytotoxicity. Blood, 2021, 138, 1172-1172.	1.4	2
137	Identification of Predictive Markers of Severe and Prolonged Neutropenia after CD19-Specific CAR T-Cell Treatment in Patients with Relapsed/Refractory B-Cell Malignancies. Blood, 2020, 136, 41-42.	1.4	1
138	PS29MRC - a Novel Predictive Score for Response to Therapy in Acute Myeloid Leukemia. Blood, 2016, 128, 1209-1209.	1.4	1
139	Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist. Blood, 2021, 138, 1178-1178.	1.4	1
140	The CAR-Hematotox Identifies Patients at High Risk for Prolonged Neutropenia, Infectious Complications and Prolonged Hospitalization Following CD19-CART in R/R LBCL. Blood, 2021, 138, 3852-3852.	1.4	1
141	Identification of Prognostic Immunophenotypes at First Diagnosis in Patients with Acute Myeloid Leukemia (AML) By a Standardized Multicolor Flow Cytometry (MFC) Panel Originally Designed to Detect Measurable Residual Disease (MRD) at Follow-up. Blood, 2020, 136, 35-35.	1.4	1
142	Treatment-Free Intervals Mitigate T-Cell Exhaustion Induced By Continuous CD19xCD3-BiTEÅ® Construct Stimulation in Vitro. Blood, 2020, 136, 44-45.	1.4	1
143	Combination of Complement-Dependent Cytotoxicity and Relative Fluorescent Quantification of HLA Length Polymorphisms Facilitates the Detection of a Loss of Heterozygosity. Bone Marrow Research, 2014, 2014, 1-9.	1.7	0
144	Future outlook for acute leukemias. , 2016, , 77-92.		0

#	ARTICLE	IF	CITATIONS
145	A fluorescence in situ hybridization-based screen allows rapid detection of adverse cytogenetic alterations in patients with acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 632-638.	2.8	0
146	Future Developments: Immunotherapy in AML. <i>Hematologic Malignancies</i> , 2021, , 339-347.	0.2	0
147	Identifying Immune Resistance Mechanisms to CD33/CD3 BiTE® Antibody Construct (AMG 330) Mediated Cytotoxicity. <i>Blood</i> , 2015, 126, 3677-3677.	1.4	0
148	ARID1A Controls a Novel Transcriptional Network Regulating FAS in Follicular Lymphoma. <i>Blood</i> , 2021, 138, 3492-3492.	1.4	0
149	Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis. <i>Blood</i> , 2021, 138, 1748-1748.	1.4	0
150	Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial. <i>Blood</i> , 2020, 136, 10-11.	1.4	0
151	Äkute Myeloische Leukämie: Eigene T-Zellen als Waffe gegen Leukämie einsetzen. , 0, , .		0